Results 41 to 50 of about 2,363,412 (175)

A narrative review of aspirin resistance in VTE prophylaxis for orthopaedic surgery

, 2020
Total hip arthroplasties (THA) and total knee arthroplasties (TKA) confer one of the highest risks for developing venous thromboembolism (VTE) and pharmacological prophylaxis is imperative to help mitigate the risks.
Nusem, I, Barras, M, Bird, R, van Oosterom, N, Cottrell, N, Neil Cottrell, Cottrell, Neil, Robert Bird, Barras, Michael, Bird, Robert, van Oosterom, Nameer, Nusem, Iulian, Nameer van Oosterom, Iulian Nusem, Michael Barras   +14 more
core   +1 more source

Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients

Journal of Translational Medicine, 2008
Background Our previous publication showed that 9% of patients with a history of myocardial infarction MI. could be labeled as aspirin resistant; all of these patients were aspirin resistant because of non-compliance.
Reeves Mathew, Barber Kimberly, Schwartz Dianne E, Schwartz Kenneth A, De Franco Anthony C   +4 more
doaj   +1 more source

CLINICAL SIGNIFICANCE OF ASPIRIN RESISTANCE IN PATIENTS WITH CARDIO-VASCULAR DISEASES

Рациональная фармакотерапия в кардиологии, 2016
Atherothrombosis is a complication of ischemic heart disease, and it leads to development of acute coronary syndrome. Atherothrombosis is characterized by sudden destruction of atherosclerotic plaque, which results into platelets activation and thrombus ...
P. J. Dovgalevsky, N. V. Furman, N. F. Puchinian   +2 more
doaj   +1 more source

Acetylsalicylic-acid (aspirin) induces resistance to tobacco mosaic-virus in tobacco

, 1979
Tobacco cv. Xanthi-nc becomes resistant to tobacco mosaic virus (TMV) and produces b proteins when injected with the interferon inducer polyacrylic acid.
White, R. F.
core   +1 more source

Aspirin strategy for secondary prevention of atherosclerotic cardiovascular diseases: A narrative review

Journal of the Practice of Cardiovascular Sciences, 2023
Aspirin is the most used antiplatelet agent for secondary prophylaxis of atherosclerotic cardiovascular diseases. Individual variability in aspirin responsiveness has been widely reported.
Nischal N Hegde, Navin Mathew
doaj   +1 more source

ASPIRIN RESISTANCE IN NEUROVASCULAR DISEASES

Acta Medica, 2014
Introduction: The issue of resistance to antiplatelet therapy has raised many questions in the area of neurovascular diseases. The first objective of this work was to determine the prevalence of aspirin resistance in neurovascular patients with clinical ...
Martin Vališ, Dagmar Krajíčková, Jaroslav Malý, Radovan Malý, Ilona Fátorová, Oldřich Vyšata, Roman Herzig   +6 more
doaj   +1 more source

Can resistance to aspirin be reversed after an additional dose?

, 2011
Estudio observacional donde se evaluó en 141 pacientes con enfermedad coronaria estable en tratamiento crónico con aspirina 100mg al día si una dosis adicional reduce el porcentaje de pacientes no respondedores al tratamiento antiagregante.
Dominick J. Angiolillo, Luis Azcona, Macaya Miguel, Carlos, Antonio Fernández-Ortiz, Carlos Macaya, Núñez Gil, Ivan, Juan Jose González-Ferrer, Angiolillo, Dominick J., David Vivas, Ivan Núñez-Gil, Vivas Balcones, Luis David, Bernardo, Esther, Azcona, Luis, Juan Carlos García-Rubira, González Ferrer, Juan José, García Rubira, Juan Carlos, Esther Bernardo, Fernández Ortiz, Antonio Ignacio   +17 more
core   +1 more source

Assessment of Risk Factors for Drug Resistance of Dual Anti Platelet Therapy After PCI

Clinical and Applied Thrombosis/Hemostasis, 2022
Since aspirin and clopidogrel are the widely and conventionally used drugs to treat acute myocardial infarction after percutaneous coronary intervention (PCI), it is important to explore potential risk factors of their resistance.
Lijie Zhang PhD, MD, Ying Lv PhD, MD, Jianyu Dong PhD, MD, Nana Wang MSc, Zhan Zhan MSc, Yuan Zhao BSc, Shanshan Jiang PhD, MD   +6 more
doaj   +1 more source

Aspirin resistance: Where are we now?

, 2013
Aspirin is an effective antiplatelet drug for preventing thrombo-embolic vascular events. However, clinical and laboratory evidence demonstrates diminished or no response to aspirin in some patients that is called aspirin resistance.
Abaci, Okay, Kilickesmez, Kadriye Orta
core   +1 more source

The potential therapeutic regimen for overcoming resistance to osimertinib due to rare mutations in NSCLC

iScience, 2023
Summary: The mechanisms of osimertinib resistance have not been well characterized. We conducted next-generation sequencing to recognize novel resistance mechanism and used cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models to ...
Rui Han, Caiyu Lin, Chong Zhang, Jun Kang, Conghua Lu, Yiming Zhang, Yubo Wang, Chen Hu, Yong He   +8 more
doaj   +1 more source